60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Equity-to-Asset : 0.63 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. 60 Degrees Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $4.87 Mil. 60 Degrees Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $7.78 Mil. Therefore, 60 Degrees Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.63.

The historical rank and industry rank for 60 Degrees Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

SXTP' s Equity-to-Asset Range Over the Past 10 Years
Min: -18.18 Med: -9.66 Max: 0.63
Current: 0.63

During the past 4 years, the highest Equity to Asset Ratio of 60 Degrees Pharmaceuticals was 0.63. The lowest was -18.18. And the median was -9.66.

SXTP's Equity-to-Asset is ranked worse than
53.42% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs SXTP: 0.63

60 Degrees Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Equity-to-Asset Chart

60 Degrees Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

-6.72

-12.61

-18.18

0.63

60 Degrees Pharmaceuticals Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial						-18.18	-2.50	-3.03	0.72	0.63

Competitive Comparison of 60 Degrees Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

60 Degrees Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's Equity-to-Asset falls into.

60 Degrees Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

60 Degrees Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	4.87	/	7.784
	=	0.63

60 Degrees Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	4.87	/	7.784
	=	0.63

60 Degrees Pharmaceuticals (NAS:SXTP) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

60 Degrees Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036

Website

https://www.60degreespharma.com

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.

Executives

Charles W Allen	director	1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc.	10 percent owner	824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Cheryl Xu	director	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Paul Field	director	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller	officer: Chief Financial Officer	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Geoffrey S Dow	director, 10 percent owner, officer: CEO and President	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc.	10 percent owner	200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith	officer: Chief Medical Officer	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey	director	1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036